Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Eli Lilly and Co    LLY

News SummaryMost relevantAll newsSector newsTweets 

Eli Lilly & Co. : Lilly quarterly sales, profit beats forecasts

share with twitter share with LinkedIn share with facebook
share via e-mail
04/25/2012 | 02:01pm CEST

Eli Lilly & Co's quarterly profit fell on plunging sales of its Zyprexa schizophrenia drug, but results handily topped Wall Street forecasts, helped by strong sales of anti-depressant Cymbalta and demand for the company's animal health products.

The earnings beat, relative to investor expectations, was also due to cost controls, surging demand in China for its products and because Zyprexa's decline was not as steep as had been feared, said company spokesman Mark Taylor.

The Indianapolis drugmaker said on Wednesday it earned $1.01 billion, or 91 cents per share in the first quarter. That compared with $1.06 billion, or 95 cents per share, in the year-earlier period, when the company took a number of restructuring and research-related charges.

Excluding special items, Lilly earned 92 cents per share. Analysts, on average, had expected 78 cents per share, according to Thomson Reuters I/B/E/S.

The company's shares rose 2.2 percent in premarket trading.

"Lilly just reported what looks like a solid first quarter," ISI Group analyst Mark Schoenebaum said in a research note.

But Schoenebaum predicted its shares would not react in a major way since investors are more focused on the company's progress in developing solanezumab, its experimental Alzheimer's disease treatment, than on quarterly earnings.

Data from the drug's late-stage trial is expected later this year. Although the drug is considered to be a long shot, investors say it would have huge sales potential if shown to slow progress of the memory-robbing disease, and speed Lilly's return to profit growth.

Global company revenue fell 4 percent to $5.6 billion, little affected by foreign exchange rates, above Wall Street expectations of $5.36 billion.

Sales of Zyprexa, which lost U.S. patent protection in October, tumbled 56 percent to $563 million, while Cymbalta sales jumped 23 percent to $1.11 billion.

Although Cymbalta's growth helped offset declines for Zyprexa in the quarter, the depression drug's own U.S. patent will lapse in mid-2013. Its sales will then shrink dramatically, worsening Lilly's long-feared patent cliff.

Global sales of Alimta, the company's lung cancer drug, rose 5 percent to $607 million. Its Humalog insulin rose 12 percent to $590 million, while its Humulin insulin brand grew 6 percent to $308 million.

The company slightly raised its 2012 profit forecast to between $3.15 and $3.30 per share, excluding special items. In January, Lilly forecast $3.10 to $3.20 per share, far below analyst estimates, sending the drugmaker's stock down sharply.

(Reporting By Ransdell Pierson; Editing by Gerald E. McCormick and Maureen Bavdek)

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ELI LILLY AND CO
03:55a ELI LILLY AND : Angela Bassett urges people with diabetes to know their heart di..
05/24 ELANCO : Animal Health Works to Bring Products to Small Holder Farmers, Increasi..
05/18 ELI LILLY AND : Findings from Eli Lilly and Company in the Area of Nucleoprotein..
05/18 ELI LILLY AND : Leigh Ann Pusey Joins Lilly as Senior Vice President of Corporat..
05/18 ELI LILLY AND : Lilly Announces Positive Results for Three Phase 3 Studies of Ga..
05/18 ELI LILLY AND : The Faces of Medicine
05/17 ELI LILLY AND : Lilly to Present Results from Pivotal Breast Cancer Study of Abe..
05/17 ELI LILLY AND CO (NYSE : LLY) Jardiance Beats Johnson & Johnson (NYSE:JNJ) Invok..
05/17 ELI LILLY AND : Ensuring Universal Access is a Political Choice
05/16 ELI LILLY AND : Actress Angela Bassett joins For Your SweetHeart™ to urge ..
More news
Sector news : Pharmaceuticals - NEC
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
05/23DJALEXION PHARMACEUTICALS : Shakeup Continues as Four Executives Exit -- 2nd Updat..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/21 WEEK IN REVIEW : Shanghai Pharma Considers $4 Billion Bid For Germany's Stada
05/19 Asco Preview - Breast Cancer And I-O Combos Grab The Early Headlines
05/19 ANAVEX LIFE SCIENCES : 5 Reasons Why I'm Short
05/19 European Ad Comm backs Sanofi's Humalog biosimilar
Financials ($)
Sales 2017 22 088 M
EBIT 2017 5 504 M
Net income 2017 3 246 M
Debt 2017 4 852 M
Yield 2017 2,68%
P/E ratio 2017 29,66
P/E ratio 2018 19,66
EV / Sales 2017 4,11x
EV / Sales 2018 4,03x
Capitalization 86 018 M
More Financials
Duration : Period :
Eli Lilly and Co Technical Analysis Chart | LLY | US5324571083 | 4-Traders
Full-screen chart
Technical analysis trends ELI LILLY AND CO
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 89,1 $
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
David A. Ricks President, Chief Executive Officer & Director
John C. Lechleiter Chairman
Derica W. Rice Chief Financial Officer & EVP-Global Services
Jan M. Lundberg Executive Vice President-Science & Technology
Kathi P. Seifert Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND CO6.04%84 936
JOHNSON & JOHNSON10.68%342 817
ROCHE HOLDING LTD.15.18%237 610
NOVARTIS AG6.68%213 719
PFIZER INC.-1.32%191 279
MERCK & CO., INC.10.29%175 160
More Results